{"schema_version":"1.0","type":"article","title":"FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.md","lang":"zh-Hant","date":"2026-06-28","publish_at":"2026-06-28T08:50:00+08:00","updated_at":"2026-06-28","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","疫苗","感染症","BD","臨床數據","生技投資"],"summary":"代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。","key_points":[],"facts":[],"sections":["01｜Operation TrialBlazer：FDA 正在告訴市場，審評效率會被重新重視","02｜Moderna：同一個 mRNA 流感疫苗，命運突然轉向","03｜uniQure：罕見病基因療法，重新看到加速核准路徑","04｜REGENXBIO：Navsunli 的回轉，更像是罕見病審查風向球","05｜XBI 反攻，不只靠 FDA，也靠 M&A 重啟","結語｜FDA 變化不是全面放水，而是讓「好資料」更快被看見"],"references":[{"title":"[0] 各公司官網與公開資料。","source":"","date":"","url":""},{"title":"[1] Barron’s","source":"[Biotech Shares Are Soaring]","date":"","url":"https://www.barrons.com/articles/biotech-shares-xbi-ff82f9cb"},{"title":"[2] FDA","source":"[Clinical Trials and Human Subject Protection]","date":"","url":"https://www.fda.gov/drugs/development-approval-process-drugs/clinical-trials-and-human-subject-protection"},{"title":"[3] FDA","source":"[Vaccines and Related Biological Products Advisory Committee]","date":"","url":"https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-and-related-biological-products-advisory-committee"},{"title":"[4] The Wall Street Journal","source":"[FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says]","date":"","url":"https://www.wsj.com/tech/biotech/fda-will-reverse-rejection-of-third-rare-disease-drug-regenxbio-says-d8fff1fc"},{"title":"[5] REGENXBIO","source":"[RGX-121 / Navsunli program information]","date":"","url":"https://www.regenxbio.com/pipeline/rgx-121/"}],"images":[{"alt":"Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 1）","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-01.png"},{"alt":"Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 2）","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-02.png"},{"alt":"Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 3）","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-03.png"},{"alt":"Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 4）","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/cover.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-28）。FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起。https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-28-fda-regulatory-shift-biotech-rebound-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}